Skip to content
DataLookout
Menu

NCT05870917

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 6 more changesShow less
    • Eligibility criteria expanded, about 45 words
    • Final enrollment: 25 participants (planned 20)
    • Primary completion date changed from estimate of Jun 2026 to Sep 18, 2025
    • Interventions modified
    • Secondary endpoints: 4 to 5
    • Study description shortened, about 2 words
  2. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Start date: Apr 25, 2023 to May 23, 2023
    • Site details revised
    v4
  3. Notable Primary completion date: Apr 2025 to Jun 2026v3
  4. Minor Study description shortened, about 20 words
    • Study title shortened, about 1 word
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression free survival (PFS)
Timeframe: 1 year
Safety and Tolerability
Timeframe: 2 year

Secondary (5)

Complete response rate (CRR)
Overall survival (OS)
MRD-negative Rate
Duration of Remission (DOR)
Overall response rate (ORR)

Arms and interventions

VRD-based regimen Combined CART-ASCT-CART2Experimental

VRD:Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle. Autologous BCMA-directed CAR T cells: two sequential intravenous infusions of the same product in each patient, either YK-BB-002 at a target dose of (2-4) × 10⁶ ± 20% CAR-positive T cells/kg or equecabtagene autoleucel at a planned dose of 1.0 × 10⁶ CAR-positive T cells/kg. Participants will receive VRD-based induction, first CAR-T infusion, VR-based consolidation, ASCT followed by the second CAR-T infusion, and R-based maintenance.

Biologicals: anti-BCMA CAR-T

Drugs: VRD-based Regimen

Sites

1 site in 1 country

  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical SciencesTianjin, China